• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

关于停药的相关内容

  [复制链接]
8789 15 老马 发表于 2013-5-14 07:55:26 |
老马  博士一年级 发表于 2013-5-14 08:04:04 | 显示全部楼层 来自: 浙江温州
摘要:这3名患者在取得稳定的分子学缓解之后(融合基因转阴PCRU)停用达沙替尼。1名患者复发,另外两名患者在1年后仍保持了PCRU。以前说过,达沙替尼确实可以提高免疫力,希望今后能获得更多的相关研究报告。5 `8 s$ }9 C: K8 R. |9 C
    关于这个研究值得注意的是,这三名患者都是服用格列卫失败后转用达沙替尼的,也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同,那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察,看看停用达沙替尼是否能持久不复发。$ _6 ]7 l) F3 I# P( t+ J) Q

. X0 x8 E' |# Z& T作者:来自澳大利亚
1 S' z8 c3 v) d7 L来源:Haematologica. 2011.8.9.( O; m: A7 `# @$ W) D; V4 T. L
Dear Group,
' C3 ^/ F5 l- j' j" n. F* A9 q( s' T
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML6 K* K9 |7 ]0 b9 B4 H  c
therapies. Here is a report from Australia on 3 patients who went off Sprycel* M! J' z& ~; o- W
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients' T4 k$ |1 S% X% ?* N( s- {7 S
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
1 b& p/ r- _: M8 Pdoes spike up the immune system so I hope more reports come out on this issue.9 a9 z" g0 Q: M8 n5 W
& n% r* H# H# R- M- U
The remarkable news about Sprycel cessation is that all 3 patients had failed2 ]) s2 j$ ~% y# O6 [; u  g; B$ |
Gleevec and Sprycel was their second TKI so they had resistant disease. This is" |4 _6 @  s- `7 F% M
different from the stopping Gleevec trial in France which only targets patients+ q" i- T6 g: @  x& @3 I6 Y
who have done well on Gleevec.# b* W. w  B) M. V* o7 L" U9 L, I

2 E4 s! c% Y! @$ D5 e3 z0 I5 [# C3 tHopefully, the doctors will report on a larger study and long-term to see if the
4 l; T# v. k0 M8 Xresponse off Sprycel is sustained." E: L1 j' P7 f! i
4 t) Y5 {" k6 n. l: F
Best Wishes,
9 O& L7 F& |; T6 h2 M9 ^) i8 I, EAnjana- r: }! W  g" _2 {+ r' a4 S, E

+ p2 C: Z$ X" p4 x5 e8 `
: V/ D' k9 _9 v2 P' M( t5 [& L7 B% {, [8 l4 w* h* `9 }' V
Haematologica. 2011 Aug 9. [Epub ahead of print]# Q: j& `( R5 x% W# W. L
Durable complete molecular remission of chronic myeloid leukemia following
& s  p! ?, U$ x8 S. p6 f, F) idasatinib cessation, despite adverse disease features.. J4 B5 W& o" [3 g: ]
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.$ g* b0 h4 [5 @
Source3 z& r. m% N1 |
Adelaide, Australia;
/ X* B& Z2 f7 Z: ?- w( [' p6 [. Q* N
Abstract8 g8 {' S& @3 T6 H/ @7 ]
Patients with chronic myeloid leukemia, treated with imatinib, who have a
8 J2 w6 N. I1 N& G- z8 sdurable complete molecular response might remain in CMR after stopping
& i& _- {7 `% r8 ~# J1 F' L( Ptreatment. Previous reports of patients stopping treatment in complete molecular
2 a) ^" Q+ B* G4 m# s% {& c- `response have included only patients with a good response to imatinib. We& w+ R6 |0 F$ h0 z! I7 e
describe three patients with stable complete molecular response on dasatinib
- C1 L% I+ A; A1 o& l* A4 w/ p* Gtreatment following imatinib failure. Two of the three patients remain in( }1 @9 q9 P: p3 U7 V+ |( W- e$ A$ I$ Q
complete molecular response more than 12 months after stopping dasatinib. In
8 Z1 [; m( U0 a5 Athese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
" c9 d) L  k) n; `6 _show that the leukemic clone remains detectable, as we have previously shown in* v# I' t4 z& Y5 N4 v0 L' X
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
3 o4 M. y4 D) y- G! v4 K4 }the emergence of clonal T cell populations, were observed both in one patient
' H% H" |  m  y/ Gwho relapsed and in one patient in remission. Our results suggest that the' r" T6 Q* k7 q1 i% `; `5 C/ D
characteristics of complete molecular response on dasatinib treatment may be
) P! e  E' s7 X3 x" \similar to that achieved with imatinib, at least in patients with adverse
2 a6 r' J  u  J  y1 Q9 ndisease features.6 e) M; O7 j5 m. n2 F. n4 W9 S
个人公众号:treeofhope

举报 使用道具

回复 支持 0 反对 1
老马  博士一年级 发表于 2013-5-14 08:04:25 | 显示全部楼层 来自: 浙江温州
摘要:(STIM试验为法国的格列卫停药试验。)这个研究中,患者先是取得了CMR(融合基因转阴),然后停用格列卫,而后复发。15名复发患者在重新服药后又一次取得了CMR,他们同意再次停药。
' W0 i' @8 e/ O( n' R4 w4 d    第一次CMR持续时间为31个月,然后患者停药,复发的中位时间为2.6个月,然后重新服用格列卫,中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后,患者同意再次停药,这次,15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR,而10名患者在停药中位时间2月后第二次复发。
( V' h2 Y( h( z' k    请注意,这些患者都是在第一次CMR后停药然后又复发的患者。5 j8 @; F. F! v- `% O& h# ^6 O0 F7 d% O
" l3 t, j: @. Q- f8 y0 d1 ?
作者:来自法国STIM试验$ X4 s; p( n, H, ~; d6 [; [7 f: A) J
来源:EHA 2011.6.会议摘要
个人公众号:treeofhope

举报 使用道具

回复 支持 0 反对 1
gjzlovemama  初中一年级 发表于 2013-5-14 23:45:09 | 显示全部楼层 来自: 山东滨州
很不错的文章,看来马老师家有考虑停药的想法了啊!祝福!

举报 使用道具

回复 支持 0 反对 1
jack_7777  禁止访问 发表于 2014-11-22 19:47:19 | 显示全部楼层 来自: 广东广州
提示: 作者被禁止或删除 内容自动屏蔽
签名被屏蔽
sdlclqm  大学一年级 发表于 2015-9-29 19:03:13 | 显示全部楼层 来自: 山东聊城
期盼易或特也能停药,但现在觉得是一个梦想!
monekyll  大学二年级 发表于 2015-10-2 12:44:50 | 显示全部楼层 来自: 广东
这个非常有意义的研究。能吃下来停会再吃,再停,那是天大的好事

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表